ELELYSO

This brand name is authorized in Canada, Israel, New Zealand, Turkey, United States, South Africa

Active ingredients

The drug ELELYSO contains one active pharmaceutical ingredient (API):

1 Taliglucerase alfa UNII 0R4NLX88O4 - TALIGLUCERASE ALFA

Taliglucerase alfa, a long term enzyme replacement therapy, is a recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside. It is used for the treatment of patients with a confirmed diagnosis of Type 1 Gaucher disease. Read about Taliglucerase alfa

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ELELYSO Powder for solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AB11		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02425637
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7154
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 18441
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681308267436
Country: US	FDA, National Drug Code	Identifier(s): 0069-0106
Country: ZA	Health Products Regulatory Authority	Identifier(s): 50/31/0316